Molecular biology and targeted therapies for urothelial carcinoma
- 1 April 2015
- journal article
- review article
- Published by Elsevier BV in Cancer Treatment Reviews
- Vol. 41 (4), 341-353
- https://doi.org/10.1016/j.ctrv.2015.03.004
Abstract
No abstract availableKeywords
This publication has 96 references indexed in Scilit:
- Oncogenic FGFR3 gene fusions in bladder cancerHuman Molecular Genetics, 2012
- Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trialThe Lancet Oncology, 2012
- mTOR Signaling in Growth Control and DiseaseCell, 2012
- Molecular mechanisms and clinical applications of angiogenesisNature, 2011
- Phase II Study of Aflibercept (VEGF-Trap) in Patients With Recurrent or Metastatic Urothelial Cancer, a California Cancer Consortium TrialUrology, 2010
- Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancerCancer and Metastasis Reviews, 2009
- Phase 2 trial of sorafenib in patients with advanced urothelial cancerCancer, 2009
- A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102Annals of Oncology, 2009
- FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancerThe Journal of Pathology, 2007
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 2001